Lung cancer is one of the deadliest types of cancer responsible for thousands of cancer-
related deaths. Its treatment has remained a challenge for researchers, but an increase in …

Abstract The management of Non-Small Cell Lung Cancer (NSCLC) has changed
dramatically in the last 10 years with an increase in the understanding of the biology and …

Inhibitory ligands on tumor cells and their corresponding receptors on T cells are collectively
called immune checkpoint molecules and have emerged as druggable targets that harness …

Lung cancer is the leading cause of cancer-related death worldwide, with a poor prognosis.
Despite aggressive treatment, progression-free survival (PFS) and overall survival are …

Chemotherapy and targeted therapy have significantly improved the progression of non-
small cell lung cancer (NSCLC), but patients are inevitably suffering from drug resistance …

Immunotherapy has emerged as a hot topic in the treatment of non-small cell lung cancer
(NSCLC) with remarkable success. Compared to chemotherapy patients, the 5-year survival …

Despite recent advances, prognosis of patients with advanced lung cancer remains dismal.
Owing to a better understanding of the interactions between immune system and tumor cells …

Non-small-cell lung cancer (NSCLC) is a major health burden, and novel therapeutic
options are needed to help solve this problem. One such option is immunotherapy, which …

Lung cancer is the leading cause of cancer-related mortality worldwide. Treatment with
immunotherapy has made a significant impact on the outcomes for those patients suffering …

Immunotherapy is a major breakthrough in the treatment of cancer in recent years. Immune
checkpoint inhibitors (ICIs) including programmed death-ligand 1 (PD-L1)/programmed …